More recently, higher titers of anti-EBV antibodies were found in newly-onset JDM patients, though with no significant statistical difference in comparison with controls: the authors found that CD3-CD16+CD56+ lymphocytes were extremely low in the earlier phases of JDM patients (17). The gene discussed is NCAM1; the disease is juvenile dermatomyositis.